These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 25903328

  • 1. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y.
    Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
    [Abstract] [Full Text] [Related]

  • 2. Editorial Comment to Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Mitsui Y.
    Int J Urol; 2015 Jul; 22(7):643-4. PubMed ID: 25903446
    [No Abstract] [Full Text] [Related]

  • 3. Role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma and the prognostic significance of C-reactive protein: A multi-institutional, retrospective study.
    Fujita K, Inamoto T, Yamamoto Y, Tanigawa G, Nakayama M, Mori N, Tsujihata M, Azuma H, Nonomura N, Uemura M.
    Int J Urol; 2015 Nov; 22(11):1006-12. PubMed ID: 26153093
    [Abstract] [Full Text] [Related]

  • 4. High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Tan YG, Eu EWC, Huang HH, Lau WKO.
    Int J Urol; 2018 Mar; 25(3):232-238. PubMed ID: 29094397
    [Abstract] [Full Text] [Related]

  • 5. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy.
    Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H, Homma Y.
    Jpn J Clin Oncol; 2013 Sep; 43(9):923-8. PubMed ID: 23888082
    [Abstract] [Full Text] [Related]

  • 6. Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.
    Dalpiaz O, Ehrlich GC, Mannweiler S, Hernández JM, Gerger A, Stojakovic T, Pummer K, Zigeuner R, Pichler M, Hutterer GC.
    BJU Int; 2014 Sep; 114(3):334-9. PubMed ID: 24053693
    [Abstract] [Full Text] [Related]

  • 7. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world.
    Taguchi S, Nakagawa T, Uemura Y, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Fujimura T, Fukuhara H, Kume H, Homma Y.
    World J Urol; 2016 Feb; 34(2):163-71. PubMed ID: 26135306
    [Abstract] [Full Text] [Related]

  • 8. Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor in Bladder Cancer and Metastatic or Unresectable Urothelial Carcinoma Patients: a Pooled Analysis of Comparative Studies.
    Wu S, Zhao X, Wang Y, Zhong Z, Zhang L, Cao J, Ai K, Xu R.
    Cell Physiol Biochem; 2018 Feb; 46(4):1352-1364. PubMed ID: 29689562
    [Abstract] [Full Text] [Related]

  • 9. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
    Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH.
    Int J Urol; 2016 May; 23(5):385-9. PubMed ID: 26992082
    [Abstract] [Full Text] [Related]

  • 10. [Clinical impact of peripheral lymphocyte counts for metastatic urothelial carcinoma patients treated with chemotherapy].
    Sekita N, Nishikawa R, Fujimura M, Takeuchi N, Ogino H, Shibata N, Omura S, Mikami K.
    Hinyokika Kiyo; 2014 May; 60(5):215-9. PubMed ID: 24894856
    [Abstract] [Full Text] [Related]

  • 11. A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M.
    Ann Surg Oncol; 2014 Nov; 21(12):4041-8. PubMed ID: 24912614
    [Abstract] [Full Text] [Related]

  • 12. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma.
    Dalpiaz O, Pichler M, Mannweiler S, Martín Hernández JM, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC.
    Br J Cancer; 2014 May 13; 110(10):2531-6. PubMed ID: 24691424
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B, Djokic M, Sipetic-Grujicic S, Grozdic Milojevic I, Vuksanovic A, Nikic P, Vukovic I, Djordjevic D, Bumbasirevic U, Tulic C.
    Urol Oncol; 2013 Nov 13; 31(8):1615-20. PubMed ID: 22521771
    [Abstract] [Full Text] [Related]

  • 14. Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma.
    Hutterer GC, Sobolev N, Ehrlich GC, Gutschi T, Stojakovic T, Mannweiler S, Pummer K, Zigeuner R, Pichler M, Dalpiaz O.
    J Clin Pathol; 2015 May 13; 68(5):351-5. PubMed ID: 25661796
    [Abstract] [Full Text] [Related]

  • 15. Impact of multimodal treatment on prognosis for patients with metastatic upper urinary tract urothelial cancer: Subanalysis of the multi-institutional nationwide case series study of the Japanese Urological Association.
    Inokuchi J, Naito S, Fujimoto H, Hara T, Sakura M, Nishiyama H, Miyazaki J, Kikuchi E, Hinotsu S, Koie T, Ohyama C, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2016 Mar 13; 23(3):224-30. PubMed ID: 26659912
    [Abstract] [Full Text] [Related]

  • 16. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK.
    Eur Urol; 2014 Dec 13; 66(6):1157-64. PubMed ID: 24630414
    [Abstract] [Full Text] [Related]

  • 17. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan 13; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 18. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S, Murai S, Shinohara N.
    Urol Oncol; 2017 Feb 13; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [Abstract] [Full Text] [Related]

  • 19. Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy.
    Huang J, Yuan Y, Wang Y, Chen Y, Kong W, Xue W, Chen H, Zhang J, Huang Y.
    Urol Oncol; 2017 Dec 13; 35(12):671.e1-671.e9. PubMed ID: 28826702
    [Abstract] [Full Text] [Related]

  • 20. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
    Toh E, Wilson J, Sebag-Montefiore D, Botterill I.
    Colorectal Dis; 2014 Mar 13; 16(3):O90-7. PubMed ID: 24148256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.